Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy

PURPOSE: Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS pathogenesis. We evaluated the humanized anti–VEGF-A monoclonal antibody, bevacizumab, in patients with HIV-KS. PATIENT...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Uldrick, Thomas S., Wyvill, Kathleen M., Kumar, Pallavi, O'Mahony, Deirdre, Bernstein, Wendy, Aleman, Karen, Polizzotto, Mark N., Steinberg, Seth M., Pittaluga, Stefania, Marshall, Vickie, Whitby, Denise, Little, Richard F., Yarchoan, Robert
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2012
Onderwerpen:
Original Reports
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3383119/
https://ncbi.nlm.nih.gov/pubmed/22430271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.6853
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items